4Q 2023 Preliminary Unaudited Total Revenue of $72-74 Million FY 2023 Preliminary Unaudited Total Revenue of $256-258 Million FY 2024 and 2025 Total Revenue Guidance Increased to More than $320 Million and $370 Million, Respectively FY 2024 Net Income Expected to Exceed $60 Million and Adjusted EBITDA(1) Expected to be $85 Million Growth Opportunities Targeting Manufacturing and New Pipeline Hyperimmune Globulin to Advance During 2024 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ADM ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Skyler Bloom - Head, Business Development & Corporate Strategy Adam Grossman – President & CEO Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Kristen Kluska - Cantor Fitzgerald Anthony Petrone - Mizuho Group Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2023 Financial Results and Corporate Update Conference Call ...

[PART I FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) This section covers financial statements, management's analysis, market risk, and controls [Item 1. Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) This section presents the Company's unaudited condensed consolidated financial statements, including balance sheets, statements of operations, changes in stockholders' equity, and cash flows, along with detailed notes explaining the financial position, performance, and significant accounting policies for the periods ended September 30, 2023, and December 31, 2022 [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This table presents the company's financial position (assets, liabilities, equity) for Sep 30, 2023, and Dec 31, 2022 Condensed Consolidated Balance Sheets | Metric | Sep 30, 2023 | Dec 31, 2022 | | :----- | :----------- | :----------- | | Total Assets | $348,996,565 | $348,461,881 | | Total Liabilities | $197,559,219 | $196,487,666 | | Total Stockholders' Equity | $151,437,346 | $151,974,215 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) This table details revenues, gross profit, operating income, and net income for Q3 and 9M ended Sep 30, 2023/2022 Condensed Consolidated Statements of Operations | Metric | 3 Months Ended Sep 30, 2023 | 3 Months Ended Sep 30, 2022 | 9 Months Ended Sep 30, 2023 | 9 Months Ended Sep 30, 2022 | | :----- | :-------------------------- | :-------------------------- | :-------------------------- | :-------------------------- | | Revenues | $67,274,598 | $41,090,137 | $184,311,323 | $104,098,237 | | Gross Profit | $24,652,585 | $9,656,641 | $57,855,578 | $21,088,081 | | Income (Loss) from Operations | $8,685,159 | $(9,316,733) | $7,398,764 | $(33,306,538) | | Net Income (Loss) | $2,565,055 | $(14,899,504) | $(10,594,467) | $(53,672,267) | | Basic EPS | $0.01 | $(0.08) | $(0.05) | $(0.27) | | Diluted EPS | $0.01 | $(0.08) | $(0.05) | $(0.27) | [Condensed Consolidated Statements of Changes in Stockholders' Equity](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Changes%20in%20Stockholders%27%20Equity) This table outlines changes in common shares, paid-in capital, and accumulated deficit impacting equity Condensed Consolidated Statements of Changes in Stockholders' Equity | Metric | Sep 30, 2023 | Dec 31, 2022 | | :----- | :----------- | :----------- | | Common Shares Outstanding | 225,958,084 | 221,816,930 | | Common Stock Amount | $22,596 | $22,182 | | Additional Paid-in Capital | $640,025,888 | $629,968,704 | | Accumulated Deficit | $(488,611,138) | $(478,016,671) | | Total Stockholders' Equity | $151,437,346 | $151,974,215 | - Net income for the three months ended September 30, 2023, was **$2,565,055**, contributing to the change in accumulated deficit[17](index=17&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This table summarizes cash flows from operating, investing, and financing activities for 9M ended Sep 30, 2023/2022 Condensed Consolidated Statements of Cash Flows | Cash Flow Activity | 9 Months Ended Sep 30, 2023 | 9 Months Ended Sep 30, 2022 | | :----------------- | :-------------------------- | :-------------------------- | | Net cash used in operating activities | $(8,795,952) | $(52,128,942) | | Net cash used in investing activities | $(3,573,786) | $(10,162,650) | | Net cash provided by financing activities | $4,961 | $46,108,494 | | Net decrease in cash and cash equivalents | $(12,364,777) | $(16,183,098) | | Cash and cash equivalents - end of period | $74,156,765 | $34,906,020 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures for the unaudited consolidated financial statements - The Company's management believes current cash, cash equivalents, projected revenue, and accounts receivable will be sufficient to fund operations through the end of fiscal 2024, anticipating positive cash flow from operations[27](index=27&type=chunk) - The Company continues to evaluate strategic alternatives and value-creating opportunities[28](index=28&type=chunk) [Note 1. ORGANIZATION AND BUSINESS](index=9&type=section&id=Note%201.%20ORGANIZATION%20AND%20BUSINESS) This note describes ADMA Biologics' core business in plasma-derived biologics for immunodeficient patients - ADMA Biologics is a commercial biopharmaceutical company specializing in plasma-derived biologics for immunodeficient patients[24](index=24&type=chunk) - The Company markets three FDA-approved products: BIVIGAM, ASCENIV, and Nabi-HB, and also provides contract manufacturing, laboratory services, and sells intermediate by-products and plasma[26](index=26&type=chunk) - As of September 30, 2023, working capital was **$231.9 million**, including **$74.2 million** in cash and cash equivalents[27](index=27&type=chunk) [Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES](index=10&type=section&id=Note%202.%20SUMMARY%20OF%20SIGNIFICANT%20ACCOUNTING%20POLICIES) This note outlines key accounting principles and significant estimates used in financial statement preparation - Financial statements are prepared in conformity with U.S. GAAP for interim information, with all intercompany balances and transactions eliminated[30](index=30&type=chunk)[31](index=31&type=chunk) - Significant estimates include rebates, accounts receivable realizable value, inventory valuation, future liquidity, and fair value of equity awards and warrants[33](index=33&type=chunk) - Accounts receivable, net of allowances, was **$0.1 million** at September 30, 2023, and December 31, 2022[35](index=35&type=chunk) [Note 3. INVENTORIES](index=14&type=section&id=Note%203.%20INVENTORIES) This note details the composition and valuation of inventories (raw materials, work-in-process, finished goods) Inventories | Inventory Component | Sep 30, 2023 | Dec 31, 2022 | | :------------------ | :----------- | :----------- | | Raw materials | $49,857,909 | $48,644,527 | | Work-in-process | $58,277,455 | $56,170,853 | | Finished goods | $54,980,741 | $58,464,667 | | Total inventories | $163,116,105 | $163,280,047 | - Inventories are carried at the lower of cost or net realizable value using the first-in, first-out method[39](index=39&type=chunk) [Note 4. INTANGIBLE ASSETS](index=15&type=section&id=Note%204.%20INTANGIBLE%20ASSETS) This note breaks down intangible assets and related amortization expenses Intangible Assets | Intangible Asset | Sep 30, 2023 Net | Dec 31, 2022 Net | | :--------------- | :--------------- | :--------------- | | Trademark and other intangible rights related to Nabi-HB | $390,481 | $829,770 | | Rights to intermediates | $86,421 | $183,645 | | Total Intangible Assets | $476,902 | $1,013,415 | - Amortization expense for intangible assets was **$0.2 million** for the three months ended September 30, 2023 and 2022, and **$0.5 million** for the nine months ended September 30, 2023 and 2022[62](index=62&type=chunk) [Note 5. PROPERTY AND EQUIPMENT](index=15&type=section&id=Note%205.%20PROPERTY%20AND%20EQUIPMENT) This note presents property and equipment, net of depreciation, and associated expenses

ADMA Biologics, Inc. (NASDAQ:ADMA) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Gary Nachman - Raymond James & Associates Anthony Petrone - Mizuho Securities Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2023 Fina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2023 Results Conference Call May 10, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Brian Lenz - EVP, Chief Financial Officer, General Manager of ADMA BioCenters Conference Call Participants Elliot Wilbur - Raymond James Anthony Petrone - Mizuho Securities Kristen Kluska - Cantor Fitzgerald Operator Good afternoon. And welcome to the ADMA Biologics Fir ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State o ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Skyler Bloom - Senior Director of Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director Brian Lenz - EVP, CFO & GM, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Securities Elliot Wilbur - Raymond James & Associates Kristen Kluska - Cantor Fitzgerald & Co. Operator Good afternoon, and welcome to the ADMA Biologics Fourth Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or Other Jur ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - President & CEO Brian Lenz - EVP, CFO & General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Elliot Wilbur - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2022 Financial Results and Corpora ...